NEW YORK – InformedDNA on Wednesday said it has acquired Coriell Life Sciences, a pharmacogenomics and clinical-decision support company.
St. Petersburg, Florida-based InformedDNA, which provides genetic counseling and genetic testing interpretation services to payors, hospital systems, and other healthcare organizations, will integrate PGx capabilities from Coriell, a Philadelphia-based company that sells solutions to large employers, payors, hospital systems, and research institutions.
The companies have begun integrating Coriell's PGx services into InformedDNA's DNAimpact precision health platform.
InformedDNA sells DNAimpact to payors and employers as a program that screens and educates members or employees and their healthcare providers about health risks, paired with genetic testing and counseling to create personalized care plans. The combined offering will also identify best-fit medications based on PGx results.
"Pharmacogenomics is a critical aspect of personalized precision healthcare, and it presents an important opportunity to expand our ability to drive better patient outcomes," InformedDNA CEO Surya Singh said in a statement, noting that Coriell has a presence selling to public employer plans, which he said are currently underserved by precision medicine.
Coriell CEO Scott Megill, who cofounded the company, will join InformedDNA in the new role of chief commercial officer.
Financial details of the transaction were not disclosed.